Moreover, besides this general property of PARP inhibitors, the use of these compounds takes advantage of the elevated propensity to display genomic instability (which is related with aggressiveness trait) of PTEN deficient glioma cells. The gene discussed is PTEN; the disease is central nervous system cancer.